Heidelberg Pharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Heidelberg Pharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Heidelberg Pharma: 5 sponsored US clinical trials, 1 recruiting.
Heidelberg Pharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plasma Cell Disorder, with 1 trials.
Upper-quartile sponsor footprint
Heidelberg Pharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer
NCT00615940
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
NCT00606632
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
NCT00087022
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
NCT00083525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Heidelberg Pharma pipeline
1 recruiting of 5 indexed (20% open); 4 completed (80%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Plasma Cell Disorder (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Heidelberg Pharma: open-pipeline peers nationwide
Peers matched on 5 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
Heidelberg Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
- Amazentis · 20% recruiting · 5 trials
Related
What to do with this Heidelberg Pharma page
5 registered trials is a research-attention snapshot, not an endorsement of Heidelberg Pharma or any single study.
- 1 of Heidelberg Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Plasma Cell Disorder is the condition Heidelberg Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Plasma Cell Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Heidelberg Pharma pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.